PROM1 and pancreatic adenocarcinoma: Most recently, Zhou et al. [94] conducted research into novel immunofluorescence and AI-based comprehensive analyses to quantify and spatially analyse CD8+ T cells and CD133+ CSCs, aiming to predict the survival outcomes of patients with pancreatic adenocarcinoma.